Trial reportThe Journal of infection2022
The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: A randomized trial.
Trial report in The Journal of infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03439657 (Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older), which is not on this map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- Bibliometric analysis and visualization mapping of herpes zoster vaccine publications from 1999 to 2024.Frontiers in medicine · 2025Pooled it
- Vaccines for preventing herpes zoster in older adults.The Cochrane database of systematic reviews · 2023Pooled it
- Immunogenicity and Safety of the Adjuvanted Respiratory Syncytial Virus Prefusion F Protein-Based Vaccine When Co-administered With the Adjuvanted Recombinant Herpes Zoster Subunit Vaccine in Adults ≥ 50 Years of Age.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Trial
- Summary of the National Advisory Committee on Immunization (NACI) Statement: Updated recommendations on herpes zoster vaccination for adults who are immunocompromised.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2026Article
- Article
- Herpes Zoster in Aging Patients: Risk Factors and Prevention Strategies.International journal of general medicine · 2026Review
- A narrative review on the effectiveness of PPSV23 vaccination in adults in China.Human vaccines & immunotherapeutics · 2025Review
- Review
- Evaluating the Immunogenicity, Efficacy, and Effectiveness of Recombinant Zoster Vaccine for Global Public Health Policy.Vaccines · 2025Review
- Immunogenicity of Recombinant Zoster Vaccine: A Systematic Review, Meta-Analysis, and Meta-Regression.Vaccines · 2024Review
- Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies.Human vaccines & immunotherapeutics · 2023Review
- Pneumococcal Vaccination in Adults: A Narrative Review of Considerations for Individualized Decision-Making.Vaccines · 2023Review
- Declines in invasive pneumococcal disease (IPD) during the COVID-19 pandemic in Los Angeles county.The Journal of infection · 2022Article
- The Saudi thoracic society guidelines for vaccinations in adult patients with chronic respiratory diseases.Annals of thoracic medicineArticle
Corrections and comments
- Commented on by
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHerpes zoster (HZ) results from reactivation of latent varicella-zoster virus. Adults at increased risk of HZ (due to immunocompromising conditions or older age) are also at risk of pneumococcal disease, both of which are preventable by vaccination. We evaluated simultaneous versus sequential administration of the adjuvanted recombinant zoster vaccine (RZV) and the 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ≥50 years.
methodsIn this phase IIIB multinational trial (NCT03439657), participants were randomized 1:1 to receive either the first RZV dose and PCV13 simultaneously followed by the second RZV dose two months later (Co-Ad, N = 449), or at two-month intervals, PCV13, the first RZV dose, and the second RZV dose sequentially (Control, N = 463). Objectives were to demonstrate that immune responses to both vaccines are non-inferior when co-administered compared to sequential administration and to evaluate the safety of their co-administration.
resultsThe RZV vaccine response rate (VRR) in the Co-Ad group was 99.1% (95% confidence interval [CI]: 97.6-99.7), meeting the VRR success criterion. Non-inferiority criteria for the Co-Ad versus Control group were also met for anti-glycoprotein E antibodies (adjusted geometric mean concentration Control/Co-Ad ratio 1.07 [95%CI: 0.99-1.16]) and all PCV13 serotypes (adjusted antibody geometric mean titer Control/Co-Ad ratios 1.02 [95%CI: 0.86-1.22] to 1.36 [95%CI: 1.07-1.73]). Upon co-administration, the frequency of solicited local adverse events was consistent with the known safety profile of each individual vaccine, whereas solicited general adverse events were within the same range as for RZV alone.
conclusionsRZV co-administered with PCV13 had an acceptable safety profile. Humoral immune responses to both vaccines were non-inferior when co-administered compared to sequential administration. These results suggest that adults may benefit from receiving RZV and a PCV at the same healthcare visit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.